Real World Evidence In The Pharmaceutical Landscape PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Real World Evidence In The Pharmaceutical Landscape PDF full book. Access full book title Real World Evidence In The Pharmaceutical Landscape.
| Author | : Sunil Dravida |
| Publisher | : Gatekeeper Press |
| Total Pages | : 249 |
| Release | : 2021-12-14 |
| Genre | : Technology & Engineering |
| ISBN | : 1662914091 |
Download Real-World Evidence in the Pharmaceutical Landscape Book in PDF, ePub and Kindle
In Real-World Evidence in the Pharmaceutical Landscape, life science industry experts Sunil Dravida and his co-authors have developed the first comprehensive overview of its kind on Real-World Data (RWD) in the pharmaceutical industry. The authors examine the challenges and opportunities in applying real-world data along the pharmaceutical continuum, from clinical development to medical affairs, health economics and outcomes, and marketing. They address the difficulties identifying the suitable data sources, ensuring compliance with privacy, security and regulatory requirements, and the big job of translating data into Real-World Evidence (RWE) to generate meaningful insights that can improve decision making by stakeholders and measurable outcomes that can enhance people’s health and well-being. This book is a must-read for those in the pharmaceutical industry involved with RWD, which includes just about every role, as healthcare is now dominated by the need for high-quality data that can enable better decision-making. This book is especially critical for those designing and leading RWD Centers of Excellence in pharmaceutical companies and the service providers supporting the RWD ecosystem.
| Author | : Sunil Dravida |
| Publisher | : |
| Total Pages | : 288 |
| Release | : 2021-10-29 |
| Genre | : |
| ISBN | : 9781662914089 |
Download Real-World Evidence in the Pharmaceutical Landscape Book in PDF, ePub and Kindle
In Real-World Evidence in the Pharmaceutical Landscape, life science industry experts Sunil Dravida and his co-authors have developed the first comprehensive overview of its kind on Real-World Data (RWD) in the pharmaceutical industry. The authors examine the challenges and opportunities in applying real-world data along the pharmaceutical continuum, from clinical development to medical affairs, health economics and outcomes, and marketing. They address the difficulties identifying the suitable data sources, ensuring compliance with privacy, security and regulatory requirements, and the big job of translating data into Real-World Evidence (RWE) to generate meaningful insights that can improve decision making by stakeholders and measurable outcomes that can enhance people's health and well-being. This book is a must-read for those in the pharmaceutical industry involved with RWD, which includes just about every role, as healthcare is now dominated by the need for high-quality data that can enable better decision-making. This book is especially critical for those designing and leading RWD Centers of Excellence in pharmaceutical companies and the service providers supporting the RWD ecosystem.
| Author | : Harry Yang |
| Publisher | : CRC Press |
| Total Pages | : 177 |
| Release | : 2021-01-11 |
| Genre | : Mathematics |
| ISBN | : 0429676816 |
Download Real-World Evidence in Drug Development and Evaluation Book in PDF, ePub and Kindle
Real-world evidence (RWE) has been at the forefront of pharmaceutical innovations. It plays an important role in transforming drug development from a process aimed at meeting regulatory expectations to an operating model that leverages data from disparate sources to aid business, regulatory, and healthcare decision making. Despite its many benefits, there is no single book systematically covering the latest development in the field. Written specifically for pharmaceutical practitioners, Real-World Evidence in Drug Development and Evaluation, presents a wide range of RWE applications throughout the lifecycle of drug product development. With contributions from experienced researchers in the pharmaceutical industry, the book discusses at length RWE opportunities, challenges, and solutions. Features Provides the first book and a single source of information on RWE in drug development Covers a broad array of topics on outcomes- and value-based RWE assessments Demonstrates proper Bayesian application and causal inference for real-world data (RWD) Presents real-world use cases to illustrate the use of advanced analytics and statistical methods to generate insights Offers a balanced discussion of practical RWE issues at hand and technical solutions suitable for practitioners with limited data science expertise
| Author | : National Academies of Sciences, Engineering, and Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 111 |
| Release | : 2016-11-07 |
| Genre | : Medical |
| ISBN | : 0309442583 |
Download Neuroscience Trials of the Future Book in PDF, ePub and Kindle
On March 3-4, 2016, the National Academies of Sciences, Engineering, and Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop in Washington, DC, bringing together key stakeholders to discuss opportunities for improving the integrity, efficiency, and validity of clinical trials for nervous system disorders. Participants in the workshop represented a range of diverse perspectives, including individuals not normally associated with traditional clinical trials. The purpose of this workshop was to generate discussion about not only what is feasible now, but what may be possible with the implementation of cutting-edge technologies in the future.
| Author | : YANG |
| Publisher | : Chapman & Hall/CRC Biostatistics Series |
| Total Pages | : 208 |
| Release | : 2021-02-16 |
| Genre | : |
| ISBN | : 9780367026219 |
Download Real-World Evidence in Drug Development and Evaluation Book in PDF, ePub and Kindle
Real-world evidence (RWE) has been at the forefront of pharmaceutical innovations. It plays an important role in transforming drug development from a process aimed at meeting regulatory expectations to an operating model that leverages data from disparate sources to aid business, regulatory, and healthcare decision making. Despite its many benefits, there is no single book systematically covering the latest development in the field. Written specifically for pharmaceutical practitioners, Real-World Evidence in Drug Development and Evaluation, presents a wide range of RWE applications throughout the lifecycle of drug product development. With contributions from experienced researchers in the pharmaceutical industry, the book discusses at length RWE opportunities, challenges, and solutions. Features Provides the first book and a single source of information on RWE in drug development Covers a broad array of topics on outcomes- and value-based RWE assessments Demonstrates proper Bayesian application and causal inference for real-world data (RWD) Presents real-world use cases to illustrate the use of advanced analytics and statistical methods to generate insights Offers a balanced discussion of practical RWE issues at hand and technical solutions suitable for practitioners with limited data science expertise
| Author | : Agency for Healthcare Research and Quality/AHRQ |
| Publisher | : Government Printing Office |
| Total Pages | : 396 |
| Release | : 2014-04-01 |
| Genre | : Medical |
| ISBN | : 1587634333 |
Download Registries for Evaluating Patient Outcomes Book in PDF, ePub and Kindle
This User’s Guide is intended to support the design, implementation, analysis, interpretation, and quality evaluation of registries created to increase understanding of patient outcomes. For the purposes of this guide, a patient registry is an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves one or more predetermined scientific, clinical, or policy purposes. A registry database is a file (or files) derived from the registry. Although registries can serve many purposes, this guide focuses on registries created for one or more of the following purposes: to describe the natural history of disease, to determine clinical effectiveness or cost-effectiveness of health care products and services, to measure or monitor safety and harm, and/or to measure quality of care. Registries are classified according to how their populations are defined. For example, product registries include patients who have been exposed to biopharmaceutical products or medical devices. Health services registries consist of patients who have had a common procedure, clinical encounter, or hospitalization. Disease or condition registries are defined by patients having the same diagnosis, such as cystic fibrosis or heart failure. The User’s Guide was created by researchers affiliated with AHRQ’s Effective Health Care Program, particularly those who participated in AHRQ’s DEcIDE (Developing Evidence to Inform Decisions About Effectiveness) program. Chapters were subject to multiple internal and external independent reviews.
| Author | : OECD |
| Publisher | : OECD Publishing |
| Total Pages | : 202 |
| Release | : 2015-10-05 |
| Genre | : |
| ISBN | : 9264244565 |
Download OECD Health Policy Studies Health Data Governance Privacy, Monitoring and Research Book in PDF, ePub and Kindle
This report identifies eight key data governance mechanisms to maximise benefits to patients and to societies from the collection, linkage and analysis of health data, and to minimise risks to both patient privacy and the security of health data.
| Author | : Raymond A. Huml |
| Publisher | : Springer Nature |
| Total Pages | : 418 |
| Release | : 2021-11-08 |
| Genre | : Medical |
| ISBN | : 3030786056 |
Download Rare Disease Drug Development Book in PDF, ePub and Kindle
This book provides a broad overview of rare disease drug development. It offers unique insights from various perspectives, including third-party capital providers, caregivers, patient advocacy groups, drug development professionals, marketing and commercial experts, and patients. A unique reference, the book begins with narratives on the many challenges faced by rare disease patient and their caregivers. Subsequent chapters underscore the critical, multidimensional role of patient advocacy groups and the novel approaches to related clinical trials, investment decisions, and the optimization of rare disease registries. The book addresses various rare disease drug development processes by disciplines such as oncology, hematology, pediatrics, and gene therapy. Chapters then address the operational aspects of drug development, including approval processes, development accelerations, and market access strategies. The book concludes with reflections on the authors' case for real-world data and evidence generation in orphan medicinal drug development. Rare Disease Drug Development is an expertly written text optimized for biopharmaceutical R&D experts, commercial experts, third-party capital providers, patient advocacy groups, patients, and caregivers.
| Author | : National Academies of Sciences, Engineering, and Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 145 |
| Release | : 2018-02-12 |
| Genre | : Medical |
| ISBN | : 0309457971 |
Download The Drug Development Paradigm in Oncology Book in PDF, ePub and Kindle
Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of effortsâ€"by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)â€"to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities. To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop.
| Author | : National Academies of Sciences, Engineering, and Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 103 |
| Release | : 2020-01-27 |
| Genre | : Medical |
| ISBN | : 0309498511 |
Download The Role of NIH in Drug Development Innovation and Its Impact on Patient Access Book in PDF, ePub and Kindle
To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€"25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop.
